Portfolio Companies News
January 30, 2023Aprea Therapeutics Appoints John Ha...
DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointmen... read more
January 23, 2023Priothera announces first patients ...
Mocravimod is the only S1PR modulator being developed to treat blood cancers and improve CAR-T therapy Phase 1b/2a data has shown mocravimod is safe and well tolerated Dublin, Ireland – January 23, 2023 – Priothera, a late-clinical stage biotechnology company pioneering th... read more
January 11, 2023Aprea Therapeutics Announces Dosing...
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the first pat... read more
January 11, 2023Oncopeptides appoints Holger Lembre...
STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has appointed Holger Lembrer as Chief Financial Officer, CFO. Prior... read more
January 10, 2023Hemab Therapeutics Announces First ...
Bispecific antibody HMB-001 positioned as the first prophylactic treatment for rare bleeding disorders CEO Benny Sorensen, MD, PhD, delivered the update during a corporate overview presented at the 41st Annual JP Morgan Healthcare Conference COPENHAGEN, DENMARK AND BOSTON, MASS., US... read more
December 23, 2022Q3 2022 General Market Overview
October 07, 2021HealthCap strengthens senior team
November 29, 2021HealthCap’s 25th company anniversary!
Since the start in 1996, HealthCap funds have invested in 126 portfolio companies.
46 of the portfolio companies have been taken public on fourteen different markets.
31 of the portfolio companies pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.
HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative...Read more